The global laboratory informatics market is experiencing a period of growth due to the acceleration of digital transformation and AI, as well as the rising use of data management tools in new markets ...

Owkin 解决了大众最担心的患者数据隐私问题，通过整合不同机构的多模态数据，加速生物标志物的发现，为精准医疗提供了可靠的决策依据，助力 ...

Artificial intelligence specialist Owkin has added another piece to its medical research portfolio with the launch of ...

Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance medical ...

Owkin’s solution is to bring academic and pharmaceutical industry researchers together in a federated research environment. Here, the company’s proprietary infrastructure and artificial ...

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective ...

Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance ...

Owkin has enticed another big pharma partner with its artificial intelligence-powered clinical development platform, Bristol-Myers Squibb, which is paying $80 million upfront to tap into its ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...

Owkin has announced a partnership with AstraZeneca to create an AI gBRCA pre-screening solution designed to identify ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...